Clinical trial
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy…
NCT04503551 · Hoffmann-La Roche, Industry · Active, not recruiting
Key facts
| NCT number | NCT04503551 |
|---|---|
| Title | A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm |
| Official title | A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy |
| Acronym | PAVILION |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Retinopathy |
| Intervention type | Drug |
| Interventions | PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection |
| Enrollment | 174 |
| Start date | Aug 10, 2020 |
| Primary completion | Oct 3, 2022 |
| Completion | Jan 31, 2026 |
| First posted | Aug 7, 2020 |
| Last update posted | Nov 25, 2025 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: